Sigma-1 Receptor Ligand Blarcamesine (ANAVEX 2-73) for Alzheimer's Disease: A Systematic Review.
Sirikalaya Brimson, Premrutai Thitilertdecha, Kishoree Krishna Kumaree et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the efficacy and safety of blarcamesine (ANAVEX 2-73) in early-stage and mild-to-moderate Alzheimer's disease (AD). The review included data from one Phase I study and two randomized clinical trials involving 509 participants. Blarcamesine was associated with slower cognitive decline and improved clinical outcomes, particularly in genetically defined subgroups, suggesting its potential as a therapeutic option for AD.
Key findings
- Blarcamesine treatment was associated with slower cognitive and functional decline in participants.
- In a randomized placebo-controlled trial, 509 participants were enrolled, with 300 remaining in the open-label extension.
- Adverse events were predominantly mild, transient, and dose-related.
- Greater therapeutic benefit was observed in participants with SIGMAR1 and COL24A1 wild-type genotypes.
Why it matters
The findings suggest that blarcamesine may offer a new oral treatment option for early-stage Alzheimer's disease, particularly for patients with specific genetic profiles. This could enhance personalized treatment approaches in dementia care.
What to keep in mind
The evidence is based on a limited number of studies, including secondary analyses and conference reports.